SCHEMBL4058036

SCHEMBL4058036

CC(C)(C)N(C(=O)O)N1CCNCC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.34
CA2 P00918 2/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA9 Q16790 1/20 0.33
HPGD P15428 1/20 0.33
CHKA P35790 1/20 0.32
CHRNB2 P17787 1/20 0.31
CHRNA3 P32297 1/20 0.31
CHRNA4 P43681 1/20 0.31
CHRNB3 Q05901 1/20 0.31
CHRNA6 Q15825 1/20 0.31
PKM P14618 1/20 0.31
HTR2A P28223 1/20 0.31
HTR2C P28335 1/20 0.31
GNAI3 P08754 1/20 0.30
GNAO1 P09471 1/20 0.30
GNAI1 P63096 1/20 0.30
OPRM1 P35372 1/20 0.30
OPRD1 P41143 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL477281 0.81 ALDH1A1 (0.33)
SCHEMBL1484414 0.74 CA2 (0.38) SIGMAR1CA2CA12CA1CA9
SCHEMBL27610692 0.68 CA2 (0.37) SIGMAR1CA2CA12CA1CA9
SCHEMBL6632262 0.68 SIGMAR1 (0.36) SIGMAR1CA2CA12CA1CA9
SCHEMBL4887482 0.66 GAA (0.38) SIGMAR1CA2CA12CA1CA9
SCHEMBL4745377 0.66 CA2 (0.38) SIGMAR1CA2CA12CA1CA9
SCHEMBL28199271 0.66 CA2 (0.38) SIGMAR1CA2CA12CA1CA9
Bicarbonate SCHEMBL6297564 0.66 CA2 (0.38) SIGMAR1CA2CA12CA1CA9
SCHEMBL30802393 0.64 CTSD (0.33) SIGMAR1CA2CA12CA1CA9
Hydrochloric Acid SCHEMBL25387507 0.64 HPGD (0.40) SIGMAR1CA2CA12CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4406606-A2 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE G Bayer Pharma Aktiengesellschaft (DE) 2024-07-31 EP disclosed
US-20230203034-A1 IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS MERCK PATENT GMBH (DE) 2023-06-29 US disclosed
EP-2863920-B1 QUINOLINE DERIVATIVES FOR USE IN THE TRATMENT OF BREAST CANCER EUTROPICS PHARMACEUTICALS INC (US) 2023-03-22 EP disclosed
US-11608338-B2 Imidazolonylquinolines and the use thereof as ATM kinase inhibitors MERCK PATENT GMBH (DE) 2023-03-21 US disclosed
EP-3868761-B1 IMIDAZOLONYLCHINOLINES AND THEIR USE AS ATM KINASE INHIBITORS MERCK PATENT GMBH (DE) 2023-03-01 EP disclosed
US-20210198257-A1 IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS MERCK PATENT GMBH (DE) 2021-07-01 US disclosed
US-10975075-B2 Imidazolonylquinolines and the use thereof as ATM kinase inhibitors MERCK PATENT GMBH (DE) 2021-04-13 US disclosed
EP-3560924-B1 IMIDAZOLONYL QUINOLINES AND THEIR USE AS ATM KINASE INHIBITORS MERCK PATENT GMBH (DE) 2021-03-31 EP disclosed
US-20200325137-A1 IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS MERCK PATENT GMBH (DE) 2020-10-15 US disclosed
CN-111747952-A Imidazoquinolinones and their use as ATM kinase inhibitors 默克专利股份公司 2020-10-09 CN disclosed
WO-2016096610-A1 ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-06-23 WO disclosed
US-20150150869-A1 METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH QUINOLINE DERIVATIVES EUTROPICS PHARMACEUTICALS, INC. 2015-06-04 US disclosed
US-20150133450-A1 METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH QUINOLINE DERIVATIVES EUTROPICS PHARMACEUTICALS INC (US) 2015-05-14 US disclosed
EP-1513531-B1 BASIC NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM MENARINI RICERCHE SPA (IT) 2009-10-21 EP disclosed
US-7491825-B2 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom MENARINI RICERCHE S.P.A. (IT) 2009-02-17 US disclosed
US-7202245-B2 Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines PFIZER INC. (US) 2007-04-10 US disclosed
US-20060205712-A1 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom MENARINI RIEERCHE S.P.A. (IT) 2006-09-14 US disclosed
EP-1513531-A1 BASIC NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM Menarini Ricerche S.p.A. (IT) 2005-03-16 EP disclosed
US-20040192698-A1 Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines PFIZER INC. 2004-09-30 US disclosed
WO-2003103671-A1 BASIC NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM MENARINI RICERCHE S.P.A. (IT) 2003-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150150869-A1 METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH QUINOLINE DERIVATIVES BCL3, BCL6, MCL1 SIGMAR1 4526/4885CA2 1931/4885CA12 2573/4885
US-20230203034-A1 IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS ATM, CHEK2, CHEK1 SIGMAR1 4336/4885CA2 4788/4885CA12 4884/4885
US-10975075-B2 Imidazolonylquinolines and the use thereof as ATM kinase inhibitors ATM, CHEK2, CHEK1 SIGMAR1 4869/4885CA2 4517/4885CA12 4884/4885
US-20060205712-A1 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom BDKRB2, BDKRB1, AGTR2 SIGMAR1 495/4885CA2 295/4885CA12 1659/4885
US-20150133450-A1 METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH QUINOLINE DERIVATIVES BCL3, BCL6, MCL1 SIGMAR1 4526/4885CA2 1931/4885CA12 2573/4885
US-20210198257-A1 IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS ATM, CHEK2, CHEK1 SIGMAR1 4336/4885CA2 4788/4885CA12 4884/4885
US-20200325137-A1 IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS ATM, CHEK2, CHEK1 SIGMAR1 4336/4885CA2 4788/4885CA12 4884/4885
US-20040192698-A1 Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines CYP4B1, CYP3A4, CYP1B1 SIGMAR1 226/4885CA2 1715/4885CA12 4049/4885
US-11608338-B2 Imidazolonylquinolines and the use thereof as ATM kinase inhibitors ATM, CHEK2, CHEK1 SIGMAR1 4336/4885CA2 4788/4885CA12 4884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.